Michael Demurjian Sells 50,000 Shares of Tyme Technologies, Inc. (NASDAQ:TYME) Stock

Tyme Technologies, Inc. (NASDAQ:TYME) COO Michael Demurjian sold 50,000 shares of Tyme Technologies stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $3.34, for a total value of $167,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Tyme Technologies, Inc. (NASDAQ:TYME) traded down $0.12 during trading hours on Monday, reaching $3.78. The company’s stock had a trading volume of 103,783 shares, compared to its average volume of 43,623. Tyme Technologies, Inc. has a 52 week low of $1.01 and a 52 week high of $9.50.

Separately, Evercore ISI assumed coverage on Tyme Technologies in a research note on Friday, November 17th. They set an “outperform” rating and a $7.00 target price on the stock.

ILLEGAL ACTIVITY WARNING: This report was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/04/insider-selling-tyme-technologies-inc-tyme-coo-sells-167000-00-in-stock.html.

Tyme Technologies Company Profile

Tyme Technologies, Inc is a clinical-stage biotechnology company. The Company is focused on developing cancer therapeutics that is intended to be broadly effective across tumor types and have low toxicity profiles. The Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system.

Receive News & Ratings for Tyme Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply